Early	O
non-persistence	B:C0243095
with	O
dabigatran	O
and	O
rivaroxaban	O
in	O
patients	O
with	O
atrial	O
fibrillation	I:C0004238
.	O

Early	O
non-persistence	O
with	O
dabigatran	B:C2348066
and	O
rivaroxaban	O
in	O
patients	O
with	O
atrial	O
fibrillation	I:C0004238
.	O

Early	O
non-persistence	O
with	O
dabigatran	O
and	O
rivaroxaban	B:C1739768
in	O
patients	O
with	O
atrial	O
fibrillation	I:C0004238
.	O

Early	O
non-persistence	O
with	O
dabigatran	O
and	O
rivaroxaban	O
in	O
patients	O
with	O
atrial	B:C0004238
fibrillation	I:C0004238
.	O

Dabigatran	B:C2348066
and	O
rivaroxaban	O
are	O
novel	O
oral	I:C0354604
anticoagulants	I:C0354604
(	O
novel	O
oral	I:C0354604
anticoagulants	I:C0354604
)	O
approved	O
for	O
stroke	O
prevention	I:C1277289
in	O
atrial	O
fibrillation	I:C0004238
(	O
atrial	O
fibrillation	I:C0004238
)	O
.	O

Dabigatran	O
and	O
rivaroxaban	B:C1739768
are	O
novel	O
oral	I:C0354604
anticoagulants	I:C0354604
(	O
novel	O
oral	I:C0354604
anticoagulants	I:C0354604
)	O
approved	O
for	O
stroke	O
prevention	I:C1277289
in	O
atrial	O
fibrillation	I:C0004238
(	O
atrial	O
fibrillation	I:C0004238
)	O
.	O

Dabigatran	O
and	O
rivaroxaban	O
are	O
novel	B:C0354604
oral	I:C0354604
anticoagulants	I:C0354604
(	O
novel	O
oral	I:C0354604
anticoagulants	I:C0354604
)	O
approved	O
for	O
stroke	O
prevention	I:C1277289
in	O
atrial	O
fibrillation	I:C0004238
(	O
atrial	O
fibrillation	I:C0004238
)	O
.	O

Dabigatran	O
and	O
rivaroxaban	O
are	O
novel	O
oral	I:C0354604
anticoagulants	I:C0354604
(	O
novel	B:C0354604
oral	I:C0354604
anticoagulants	I:C0354604
)	O
approved	O
for	O
stroke	O
prevention	I:C1277289
in	O
atrial	O
fibrillation	I:C0004238
(	O
atrial	O
fibrillation	I:C0004238
)	O
.	O

Dabigatran	O
and	O
rivaroxaban	O
are	O
novel	O
oral	I:C0354604
anticoagulants	I:C0354604
(	O
novel	O
oral	I:C0354604
anticoagulants	I:C0354604
)	O
approved	O
for	O
stroke	B:C1277289
prevention	I:C1277289
in	O
atrial	O
fibrillation	I:C0004238
(	O
atrial	O
fibrillation	I:C0004238
)	O
.	O

Dabigatran	O
and	O
rivaroxaban	O
are	O
novel	O
oral	I:C0354604
anticoagulants	I:C0354604
(	O
novel	O
oral	I:C0354604
anticoagulants	I:C0354604
)	O
approved	O
for	O
stroke	O
prevention	I:C1277289
in	O
atrial	B:C0004238
fibrillation	I:C0004238
(	O
atrial	O
fibrillation	I:C0004238
)	O
.	O

Dabigatran	O
and	O
rivaroxaban	O
are	O
novel	O
oral	I:C0354604
anticoagulants	I:C0354604
(	O
novel	O
oral	I:C0354604
anticoagulants	I:C0354604
)	O
approved	O
for	O
stroke	O
prevention	I:C1277289
in	O
atrial	O
fibrillation	I:C0004238
(	O
atrial	B:C0004238
fibrillation	I:C0004238
)	O
.	O

Although	O
novel	B:C0354604
oral	I:C0354604
anticoagulants	I:C0354604
are	O
more	O
convenient	O
than	O
warfarin	O
,	O
their	O
lack	O
of	O
monitoring	O
may	O
predispose	O
patients	O
to	O
non-persistence	O
.	O

Although	O
novel	O
oral	I:C0354604
anticoagulants	I:C0354604
are	O
more	O
convenient	O
than	O
warfarin	B:C0043031
,	O
their	O
lack	O
of	O
monitoring	O
may	O
predispose	O
patients	O
to	O
non-persistence	O
.	O

Although	O
novel	O
oral	I:C0354604
anticoagulants	I:C0354604
are	O
more	O
convenient	O
than	O
warfarin	O
,	O
their	O
lack	O
of	O
monitoring	B:C1283169
may	O
predispose	O
patients	O
to	O
non-persistence	O
.	O

Although	O
novel	O
oral	I:C0354604
anticoagulants	I:C0354604
are	O
more	O
convenient	O
than	O
warfarin	O
,	O
their	O
lack	O
of	O
monitoring	O
may	O
predispose	O
patients	O
to	O
non-persistence	B:C0243095
.	O

Limited	O
information	O
is	O
available	O
on	O
NOAC	B:C0354604
non-persistence	O
rates	O
and	O
related	O
clinical	O
outcomes	O
in	O
clinical	O
practice	I:C0282574
.	O

Limited	O
information	O
is	O
available	O
on	O
NOAC	O
non-persistence	B:C0243095
rates	O
and	O
related	O
clinical	O
outcomes	O
in	O
clinical	O
practice	I:C0282574
.	O

Limited	O
information	O
is	O
available	O
on	O
NOAC	O
non-persistence	O
rates	O
and	O
related	O
clinical	O
outcomes	O
in	O
clinical	B:C0282574
practice	I:C0282574
.	O

We	O
conducted	O
a	O
retrospective	B:C2985505
cohort	I:C2985505
study	I:C2985505
using	O
administrative	O
data	I:C0282574
from	O
Ontario	O
,	O
Canada	O
,	O
from	O
January	O
1998	O
to	O
March	O
2014	O
of	O
patients	O
with	O
atrial	O
fibrillation	I:C0004238
who	O
were	O
dispensed	O
dabigatran	O
or	O
rivaroxaban	O
.	O

We	O
conducted	O
a	O
retrospective	O
cohort	I:C2985505
study	I:C2985505
using	O
administrative	B:C0282574
data	I:C0282574
from	O
Ontario	O
,	O
Canada	O
,	O
from	O
January	O
1998	O
to	O
March	O
2014	O
of	O
patients	O
with	O
atrial	O
fibrillation	I:C0004238
who	O
were	O
dispensed	O
dabigatran	O
or	O
rivaroxaban	O
.	O

We	O
conducted	O
a	O
retrospective	O
cohort	I:C2985505
study	I:C2985505
using	O
administrative	O
data	I:C0282574
from	O
Ontario	B:C0029040
,	O
Canada	O
,	O
from	O
January	O
1998	O
to	O
March	O
2014	O
of	O
patients	O
with	O
atrial	O
fibrillation	I:C0004238
who	O
were	O
dispensed	O
dabigatran	O
or	O
rivaroxaban	O
.	O

We	O
conducted	O
a	O
retrospective	O
cohort	I:C2985505
study	I:C2985505
using	O
administrative	O
data	I:C0282574
from	O
Ontario	O
,	O
Canada	B:C0006823
,	O
from	O
January	O
1998	O
to	O
March	O
2014	O
of	O
patients	O
with	O
atrial	O
fibrillation	I:C0004238
who	O
were	O
dispensed	O
dabigatran	O
or	O
rivaroxaban	O
.	O

We	O
conducted	O
a	O
retrospective	O
cohort	I:C2985505
study	I:C2985505
using	O
administrative	O
data	I:C0282574
from	O
Ontario	O
,	O
Canada	O
,	O
from	O
January	O
1998	O
to	O
March	O
2014	O
of	O
patients	O
with	O
atrial	B:C0004238
fibrillation	I:C0004238
who	O
were	O
dispensed	O
dabigatran	O
or	O
rivaroxaban	O
.	O

We	O
conducted	O
a	O
retrospective	O
cohort	I:C2985505
study	I:C2985505
using	O
administrative	O
data	I:C0282574
from	O
Ontario	O
,	O
Canada	O
,	O
from	O
January	O
1998	O
to	O
March	O
2014	O
of	O
patients	O
with	O
atrial	O
fibrillation	I:C0004238
who	O
were	O
dispensed	B:C1880359
dabigatran	O
or	O
rivaroxaban	O
.	O

We	O
conducted	O
a	O
retrospective	O
cohort	I:C2985505
study	I:C2985505
using	O
administrative	O
data	I:C0282574
from	O
Ontario	O
,	O
Canada	O
,	O
from	O
January	O
1998	O
to	O
March	O
2014	O
of	O
patients	O
with	O
atrial	O
fibrillation	I:C0004238
who	O
were	O
dispensed	O
dabigatran	B:C2348066
or	O
rivaroxaban	O
.	O

We	O
conducted	O
a	O
retrospective	O
cohort	I:C2985505
study	I:C2985505
using	O
administrative	O
data	I:C0282574
from	O
Ontario	O
,	O
Canada	O
,	O
from	O
January	O
1998	O
to	O
March	O
2014	O
of	O
patients	O
with	O
atrial	O
fibrillation	I:C0004238
who	O
were	O
dispensed	O
dabigatran	O
or	O
rivaroxaban	B:C1739768
.	O

Non-persistence	B:C0243095
was	O
defined	O
as	O
a	O
gap	O
in	O
dabigatran	O
or	O
rivaroxaban	O
prescriptions	O
≥	O
14	O
days	O
.	O

Non-persistence	O
was	O
defined	O
as	O
a	O
gap	O
in	O
dabigatran	B:C2348066
or	O
rivaroxaban	O
prescriptions	O
≥	O
14	O
days	O
.	O

Non-persistence	O
was	O
defined	O
as	O
a	O
gap	O
in	O
dabigatran	O
or	O
rivaroxaban	B:C1739768
prescriptions	O
≥	O
14	O
days	O
.	O

Non-persistence	O
was	O
defined	O
as	O
a	O
gap	O
in	O
dabigatran	O
or	O
rivaroxaban	O
prescriptions	B:C0033081
≥	O
14	O
days	O
.	O

A	O
multivariable	B:C3161035
Cox	I:C3161035
proportional	I:C3161035
hazards	I:C3161035
model	I:C3161035
was	O
used	O
to	O
estimate	O
the	O
primary	O
composite	O
outcome	O
of	O
stroke	O
,	O
transient	O
ischaemic	I:C0007787
attack	I:C0007787
(	O
transient	O
ischaemic	I:C0007787
attack	I:C0007787
)	O
and	O
mortality	O
associated	O
with	O
non-persistence	O
.	O

A	O
multivariable	O
Cox	I:C3161035
proportional	I:C3161035
hazards	I:C3161035
model	I:C3161035
was	O
used	O
to	O
estimate	O
the	O
primary	O
composite	O
outcome	O
of	O
stroke	B:C0038454
,	O
transient	O
ischaemic	I:C0007787
attack	I:C0007787
(	O
transient	O
ischaemic	I:C0007787
attack	I:C0007787
)	O
and	O
mortality	O
associated	O
with	O
non-persistence	O
.	O

A	O
multivariable	O
Cox	I:C3161035
proportional	I:C3161035
hazards	I:C3161035
model	I:C3161035
was	O
used	O
to	O
estimate	O
the	O
primary	O
composite	O
outcome	O
of	O
stroke	O
,	O
transient	B:C0007787
ischaemic	I:C0007787
attack	I:C0007787
(	O
transient	O
ischaemic	I:C0007787
attack	I:C0007787
)	O
and	O
mortality	O
associated	O
with	O
non-persistence	O
.	O

A	O
multivariable	O
Cox	I:C3161035
proportional	I:C3161035
hazards	I:C3161035
model	I:C3161035
was	O
used	O
to	O
estimate	O
the	O
primary	O
composite	O
outcome	O
of	O
stroke	O
,	O
transient	O
ischaemic	I:C0007787
attack	I:C0007787
(	O
transient	B:C0007787
ischaemic	I:C0007787
attack	I:C0007787
)	O
and	O
mortality	O
associated	O
with	O
non-persistence	O
.	O

A	O
multivariable	O
Cox	I:C3161035
proportional	I:C3161035
hazards	I:C3161035
model	I:C3161035
was	O
used	O
to	O
estimate	O
the	O
primary	O
composite	O
outcome	O
of	O
stroke	O
,	O
transient	O
ischaemic	I:C0007787
attack	I:C0007787
(	O
transient	O
ischaemic	I:C0007787
attack	I:C0007787
)	O
and	O
mortality	O
associated	O
with	O
non-persistence	B:C0243095
.	O

The	O
cohort	B:C0599755
consisted	O
of	O
15	O
857	O
dabigatran	O
(	O
age	O
80.7±6.7	O
year	O
)	O
and	O
10	O
119	O
rivaroxaban	O
users	O
(	O
age	O
77.0	O
±7.1	O
year	O
)	O
with	O
women	O
comprising	O
52	O
%	O
of	O
each	O
medication	O
group	I:C1257890
.	O

The	O
cohort	O
consisted	O
of	O
15	O
857	O
dabigatran	B:C2348066
(	O
age	O
80.7±6.7	O
year	O
)	O
and	O
10	O
119	O
rivaroxaban	O
users	O
(	O
age	O
77.0	O
±7.1	O
year	O
)	O
with	O
women	O
comprising	O
52	O
%	O
of	O
each	O
medication	O
group	I:C1257890
.	O

The	O
cohort	O
consisted	O
of	O
15	O
857	O
dabigatran	O
(	O
age	O
80.7±6.7	O
year	O
)	O
and	O
10	O
119	O
rivaroxaban	B:C1739768
users	O
(	O
age	O
77.0	O
±7.1	O
year	O
)	O
with	O
women	O
comprising	O
52	O
%	O
of	O
each	O
medication	O
group	I:C1257890
.	O

The	O
cohort	O
consisted	O
of	O
15	O
857	O
dabigatran	O
(	O
age	O
80.7±6.7	O
year	O
)	O
and	O
10	O
119	O
rivaroxaban	O
users	O
(	O
age	O
77.0	O
±7.1	O
year	O
)	O
with	O
women	B:C0043210
comprising	O
52	O
%	O
of	O
each	O
medication	O
group	I:C1257890
.	O

The	O
cohort	O
consisted	O
of	O
15	O
857	O
dabigatran	O
(	O
age	O
80.7±6.7	O
year	O
)	O
and	O
10	O
119	O
rivaroxaban	O
users	O
(	O
age	O
77.0	O
±7.1	O
year	O
)	O
with	O
women	O
comprising	O
52	O
%	O
of	O
each	O
medication	B:C1257890
group	I:C1257890
.	O

At	O
6	O
months	O
,	O
36.4	O
%	O
of	O
patients	O
were	O
non-persistent	B:C0243095
to	O
dabigatran	O
,	O
while	O
31.9	O
%	O
of	O
patients	O
were	O
non-persistent	O
to	O
rivaroxaban	O
.	O

At	O
6	O
months	O
,	O
36.4	O
%	O
of	O
patients	O
were	O
non-persistent	O
to	O
dabigatran	B:C2348066
,	O
while	O
31.9	O
%	O
of	O
patients	O
were	O
non-persistent	O
to	O
rivaroxaban	O
.	O

At	O
6	O
months	O
,	O
36.4	O
%	O
of	O
patients	O
were	O
non-persistent	O
to	O
dabigatran	O
,	O
while	O
31.9	O
%	O
of	O
patients	O
were	O
non-persistent	B:C0243095
to	O
rivaroxaban	O
.	O

At	O
6	O
months	O
,	O
36.4	O
%	O
of	O
patients	O
were	O
non-persistent	O
to	O
dabigatran	O
,	O
while	O
31.9	O
%	O
of	O
patients	O
were	O
non-persistent	O
to	O
rivaroxaban	B:C1739768
.	O

Stroke	B:C0038454
/	O
transient	O
ischaemic	I:C0007787
attack	I:C0007787
/	O
death	O
was	O
significantly	O
higher	O
for	O
those	O
non-persistent	O
to	O
dabigatran	O
(	O
HR	O
1.76	O
(	O
95	O
%	O
CI	O
1.60	O
to	O
1.94	O
)	O
;	O
p<0.0001	O
)	O
or	O
rivaroxaban	O
(	O
HR	O
1.89	O
(	O
95	O
%	O
CI	O
1.64	O
to	O
2.19	O
)	O
;	O
p<0.0001	O
)	O
compared	O
with	O
those	O
who	O
were	O
persistent	O
.	O

Stroke	O
/	O
transient	B:C0007787
ischaemic	I:C0007787
attack	I:C0007787
/	O
death	O
was	O
significantly	O
higher	O
for	O
those	O
non-persistent	O
to	O
dabigatran	O
(	O
HR	O
1.76	O
(	O
95	O
%	O
CI	O
1.60	O
to	O
1.94	O
)	O
;	O
p<0.0001	O
)	O
or	O
rivaroxaban	O
(	O
HR	O
1.89	O
(	O
95	O
%	O
CI	O
1.64	O
to	O
2.19	O
)	O
;	O
p<0.0001	O
)	O
compared	O
with	O
those	O
who	O
were	O
persistent	O
.	O

Stroke	O
/	O
transient	O
ischaemic	I:C0007787
attack	I:C0007787
/	O
death	B:C0011065
was	O
significantly	O
higher	O
for	O
those	O
non-persistent	O
to	O
dabigatran	O
(	O
HR	O
1.76	O
(	O
95	O
%	O
CI	O
1.60	O
to	O
1.94	O
)	O
;	O
p<0.0001	O
)	O
or	O
rivaroxaban	O
(	O
HR	O
1.89	O
(	O
95	O
%	O
CI	O
1.64	O
to	O
2.19	O
)	O
;	O
p<0.0001	O
)	O
compared	O
with	O
those	O
who	O
were	O
persistent	O
.	O

Stroke	O
/	O
transient	O
ischaemic	I:C0007787
attack	I:C0007787
/	O
death	O
was	O
significantly	O
higher	O
for	O
those	O
non-persistent	B:C0243095
to	O
dabigatran	O
(	O
HR	O
1.76	O
(	O
95	O
%	O
CI	O
1.60	O
to	O
1.94	O
)	O
;	O
p<0.0001	O
)	O
or	O
rivaroxaban	O
(	O
HR	O
1.89	O
(	O
95	O
%	O
CI	O
1.64	O
to	O
2.19	O
)	O
;	O
p<0.0001	O
)	O
compared	O
with	O
those	O
who	O
were	O
persistent	O
.	O

Stroke	O
/	O
transient	O
ischaemic	I:C0007787
attack	I:C0007787
/	O
death	O
was	O
significantly	O
higher	O
for	O
those	O
non-persistent	O
to	O
dabigatran	B:C2348066
(	O
HR	O
1.76	O
(	O
95	O
%	O
CI	O
1.60	O
to	O
1.94	O
)	O
;	O
p<0.0001	O
)	O
or	O
rivaroxaban	O
(	O
HR	O
1.89	O
(	O
95	O
%	O
CI	O
1.64	O
to	O
2.19	O
)	O
;	O
p<0.0001	O
)	O
compared	O
with	O
those	O
who	O
were	O
persistent	O
.	O

Stroke	O
/	O
transient	O
ischaemic	I:C0007787
attack	I:C0007787
/	O
death	O
was	O
significantly	O
higher	O
for	O
those	O
non-persistent	O
to	O
dabigatran	O
(	O
HR	O
1.76	O
(	O
95	O
%	O
CI	O
1.60	O
to	O
1.94	O
)	O
;	O
p<0.0001	O
)	O
or	O
rivaroxaban	B:C1739768
(	O
HR	O
1.89	O
(	O
95	O
%	O
CI	O
1.64	O
to	O
2.19	O
)	O
;	O
p<0.0001	O
)	O
compared	O
with	O
those	O
who	O
were	O
persistent	O
.	O

Risk	O
of	O
stroke	B:C0038454
/	O
transient	O
ischaemic	I:C0007787
attack	I:C0007787
was	O
markedly	O
higher	O
in	O
non-persistent	O
patients	O
to	O
dabigatran	O
(	O
HR	O
3.75	O
(	O
95	O
%	O
CI	O
2.59	O
to	O
5.43	O
)	O
;	O
p<0.0001	O
)	O
and	O
rivaroxaban	O
(	O
HR	O
6.25	O
(	O
95	O
%	O
CI	O
3.37	O
to	O
11.58	O
)	O
;	O
p<0.0001	O
)	O
than	O
those	O
persistent	O
.	O

Risk	O
of	O
stroke	O
/	O
transient	B:C0007787
ischaemic	I:C0007787
attack	I:C0007787
was	O
markedly	O
higher	O
in	O
non-persistent	O
patients	O
to	O
dabigatran	O
(	O
HR	O
3.75	O
(	O
95	O
%	O
CI	O
2.59	O
to	O
5.43	O
)	O
;	O
p<0.0001	O
)	O
and	O
rivaroxaban	O
(	O
HR	O
6.25	O
(	O
95	O
%	O
CI	O
3.37	O
to	O
11.58	O
)	O
;	O
p<0.0001	O
)	O
than	O
those	O
persistent	O
.	O

Risk	O
of	O
stroke	O
/	O
transient	O
ischaemic	I:C0007787
attack	I:C0007787
was	O
markedly	O
higher	O
in	O
non-persistent	B:C0243095
patients	O
to	O
dabigatran	O
(	O
HR	O
3.75	O
(	O
95	O
%	O
CI	O
2.59	O
to	O
5.43	O
)	O
;	O
p<0.0001	O
)	O
and	O
rivaroxaban	O
(	O
HR	O
6.25	O
(	O
95	O
%	O
CI	O
3.37	O
to	O
11.58	O
)	O
;	O
p<0.0001	O
)	O
than	O
those	O
persistent	O
.	O

Risk	O
of	O
stroke	O
/	O
transient	O
ischaemic	I:C0007787
attack	I:C0007787
was	O
markedly	O
higher	O
in	O
non-persistent	O
patients	O
to	O
dabigatran	B:C2348066
(	O
HR	O
3.75	O
(	O
95	O
%	O
CI	O
2.59	O
to	O
5.43	O
)	O
;	O
p<0.0001	O
)	O
and	O
rivaroxaban	O
(	O
HR	O
6.25	O
(	O
95	O
%	O
CI	O
3.37	O
to	O
11.58	O
)	O
;	O
p<0.0001	O
)	O
than	O
those	O
persistent	O
.	O

Risk	O
of	O
stroke	O
/	O
transient	O
ischaemic	I:C0007787
attack	I:C0007787
was	O
markedly	O
higher	O
in	O
non-persistent	O
patients	O
to	O
dabigatran	O
(	O
HR	O
3.75	O
(	O
95	O
%	O
CI	O
2.59	O
to	O
5.43	O
)	O
;	O
p<0.0001	O
)	O
and	O
rivaroxaban	B:C1739768
(	O
HR	O
6.25	O
(	O
95	O
%	O
CI	O
3.37	O
to	O
11.58	O
)	O
;	O
p<0.0001	O
)	O
than	O
those	O
persistent	O
.	O

NOAC	B:C0354604
non-persistence	O
rates	O
are	O
high	O
in	O
clinical	O
practice	I:C0282574
,	O
with	O
approximately	O
one	O
in	O
three	O
patients	O
becoming	O
non-persistent	O
to	O
dabigatran	O
or	O
rivaroxaban	O
within	O
6	O
months	O
after	O
drug	O
initiation	O
.	O

NOAC	O
non-persistence	B:C0243095
rates	O
are	O
high	O
in	O
clinical	O
practice	I:C0282574
,	O
with	O
approximately	O
one	O
in	O
three	O
patients	O
becoming	O
non-persistent	O
to	O
dabigatran	O
or	O
rivaroxaban	O
within	O
6	O
months	O
after	O
drug	O
initiation	O
.	O

NOAC	O
non-persistence	O
rates	O
are	O
high	O
in	O
clinical	B:C0282574
practice	I:C0282574
,	O
with	O
approximately	O
one	O
in	O
three	O
patients	O
becoming	O
non-persistent	O
to	O
dabigatran	O
or	O
rivaroxaban	O
within	O
6	O
months	O
after	O
drug	O
initiation	O
.	O

NOAC	O
non-persistence	O
rates	O
are	O
high	O
in	O
clinical	O
practice	I:C0282574
,	O
with	O
approximately	O
one	O
in	O
three	O
patients	O
becoming	O
non-persistent	B:C0243095
to	O
dabigatran	O
or	O
rivaroxaban	O
within	O
6	O
months	O
after	O
drug	O
initiation	O
.	O

NOAC	O
non-persistence	O
rates	O
are	O
high	O
in	O
clinical	O
practice	I:C0282574
,	O
with	O
approximately	O
one	O
in	O
three	O
patients	O
becoming	O
non-persistent	O
to	O
dabigatran	B:C2348066
or	O
rivaroxaban	O
within	O
6	O
months	O
after	O
drug	O
initiation	O
.	O

NOAC	O
non-persistence	O
rates	O
are	O
high	O
in	O
clinical	O
practice	I:C0282574
,	O
with	O
approximately	O
one	O
in	O
three	O
patients	O
becoming	O
non-persistent	O
to	O
dabigatran	O
or	O
rivaroxaban	B:C1739768
within	O
6	O
months	O
after	O
drug	O
initiation	O
.	O

NOAC	O
non-persistence	O
rates	O
are	O
high	O
in	O
clinical	O
practice	I:C0282574
,	O
with	O
approximately	O
one	O
in	O
three	O
patients	O
becoming	O
non-persistent	O
to	O
dabigatran	O
or	O
rivaroxaban	O
within	O
6	O
months	O
after	O
drug	B:C0013227
initiation	O
.	O

Non-persistence	B:C0243095
with	O
either	O
dabigatran	O
or	O
rivaroxaban	O
is	O
significantly	O
associated	O
with	O
worse	O
clinical	O
outcomes	O
of	O
stroke	O
/	O
transient	O
ischaemic	I:C0007787
attack	I:C0007787
/	O
death	O
.	O

Non-persistence	O
with	O
either	O
dabigatran	B:C2348066
or	O
rivaroxaban	O
is	O
significantly	O
associated	O
with	O
worse	O
clinical	O
outcomes	O
of	O
stroke	O
/	O
transient	O
ischaemic	I:C0007787
attack	I:C0007787
/	O
death	O
.	O

Non-persistence	O
with	O
either	O
dabigatran	O
or	O
rivaroxaban	B:C1739768
is	O
significantly	O
associated	O
with	O
worse	O
clinical	O
outcomes	O
of	O
stroke	O
/	O
transient	O
ischaemic	I:C0007787
attack	I:C0007787
/	O
death	O
.	O

Non-persistence	O
with	O
either	O
dabigatran	O
or	O
rivaroxaban	O
is	O
significantly	O
associated	O
with	O
worse	O
clinical	O
outcomes	O
of	O
stroke	B:C0038454
/	O
transient	O
ischaemic	I:C0007787
attack	I:C0007787
/	O
death	O
.	O

Non-persistence	O
with	O
either	O
dabigatran	O
or	O
rivaroxaban	O
is	O
significantly	O
associated	O
with	O
worse	O
clinical	O
outcomes	O
of	O
stroke	O
/	O
transient	B:C0007787
ischaemic	I:C0007787
attack	I:C0007787
/	O
death	O
.	O

Non-persistence	O
with	O
either	O
dabigatran	O
or	O
rivaroxaban	O
is	O
significantly	O
associated	O
with	O
worse	O
clinical	O
outcomes	O
of	O
stroke	O
/	O
transient	O
ischaemic	I:C0007787
attack	I:C0007787
/	O
death	B:C0011065
.	O

